Psoriatic Arthritis
Men with inflammatory joint diseases have more children than those without IJDs
Men with inflammatory joint diseases have more children and are less likely to be childless, compared with those without inflammatory joint diseases, according to data published in the Annals of the Rheumatic Diseases.
Guselkumab efficacious in biologic-naïve patients with PsA, those unresponsive to TNFi
Guselkumab demonstrates consistent pharmacological effects across both patients naïve to biologics and those with an inadequate response to TNF inhibitors, according data published in Arthritis & Rheumatology.
Bimekizumab’s efficacy ‘favorable’ in psoriatic arthritis vs other approved treatments
Bimekizumab’s efficacy in psoriatic arthritis is “favorable” when compared with all other approved treatments in terms of both efficacy and safety, according to a systemic review and network meta-analysis published in Rheumatology.
Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand
Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.
Obstetric outcomes unaffected by maintaining TNF inhibition during pregnancy
SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.
Three-quarters of patients in RA remission flare within 3 years of TNF inhibitor taper
SAN DIEGO — Approximately 75% of patients in rheumatoid arthritis remission who taper TNF inhibitors to withdrawal experience a flare within 3 years, according to data presented at ACR Convergence 2023.
Early benefit with guselkumab predicts lower psoriatic arthritis progression at 2 years
Among patients with psoriatic arthritis treated with guselkumab, early joint improvement by week 8 predicts lower radiographic progression rates through 2 years, according to data published in Clinical Rheumatology.
‘Tough to say’: Complications, guarded optimism surround Medicare price negotiations
Following HHS’ blockbuster announcement of the first 10 drugs that would be subject to Medicare price negotiations, patients and providers alike have been looking forward to meaningful reductions in their costly treatments.
Immunosuppressed patients may accrue skin cancer at higher rates than healthy patients
Patients with certain autoimmune and inflammatory conditions may develop cutaneous squamous cell carcinoma at higher rates than immunocompetent patients, according to a study.
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.